Acumen Pharmaceuticals (ABOS) Other Non-Current Liabilities (2023 - 2025)

Acumen Pharmaceuticals (ABOS) posted Other Non-Current Liabilities of $39000.0 for Q3 2025, down 49.35% sequentially from $77000.0 in Q2 2025.

Acumen Pharmaceuticals (ABOS) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends

Acumen Pharmaceuticals has reported Other Non-Current Liabilities for 3 years, with the latest figure at $39000.0 in Q3 2025.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $39000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $39000.0 (changed N/A YoY) and the FY2024 annual result came in at $150000.0, down 47.18% from the prior year.
Other Non-Current Liabilities retreated to $39000.0 in Q3 2025 per ABOS's latest filing, from $77000.0 in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $284000.0 in Q4 2023 and troughed at $39000.0 in Q3 2025.
A 3-year average of $132800.0 and a median of $114000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
The widest YoY moves for Other Non-Current Liabilities: up 47.18% in 2024, down 47.18% in 2024.
Over 3 years, Other Non-Current Liabilities stood at $284000.0 in 2023, then sank by 47.18% to $150000.0 in 2024, then sank by 74.0% to $39000.0 in 2025.
According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $39000.0, $77000.0, and $114000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Acumen Pharmaceuticals	226.87 Mn	226.87 Mn	-

Download Data